GeminiBio Launches AI Service to Tackle Cell Therapy Manufacturing Costs

WEST SACRAMENTO, CA – February 10, 2026 – In a move aimed at addressing critical bottlenecks in the production of advanced medicines, raw materials supplier GeminiBio has launched aiMOS™ (Artificial Intelligence Media Optimization Service), a novel service that uses artificial intelligence to design custom nutrient broths for cell therapy manufacturing. The service, developed in collaboration with UK-based AI specialist Tolemy Bio, promises to make the production of life-saving cell therapies like T-cell and NK-cell therapies more efficient, consistent, and scalable.

The announcement represents a significant step in applying advanced computational science to one of the most complex and expensive areas of modern medicine. By moving away from traditional, iterative lab work, the partners aim to reduce development timelines and lower the notoriously high cost per dose that has limited patient access to these revolutionary treatments.

From Trial-and-Error to AI-Driven Precision

For decades, developing the ideal cell culture media—the nutrient-rich liquid cells grow in—has been more of an art than a science, relying on laborious trial-and-error experiments. This empirical approach is slow, costly, and often results in media that is not perfectly suited for a specific therapeutic process, leading to inconsistent batch quality and lower yields.

GeminiBio’s new aiMOS™ service seeks to replace this paradigm with data-driven precision. It leverages Tolemy Bio’s ‘Orbit’ platform, which applies causal AI modeling to multi-omics data. By analyzing a cell’s metabolic and behavioral “fingerprints,” the system aims to understand the precise cause-and-effect relationships between media components and cell performance.

“Cell therapy developers shouldn’t have to accept one-size-fits-all media when their processes, cell sources, and activation strategies are so different,” said Brian Parker, Chief Executive Officer at GeminiBio, in a statement. “aiMOS reads what the cells are telling us in culture, designs a tailored media supplement, and then takes that formulation all the way to cGMP.”

This is a departure from conventional machine learning, which often identifies correlations without explaining causation. By pinpointing the specific biological levers that control cell health, potency, and yield, the platform can predict the ideal supplement composition needed to achieve desired outcomes.

“By applying causal AI modelling to a cell’s metabolic and behavioral fingerprints, our platform can identify the exact levers that drive cell therapy performance, potency and yield,” explained Alex Ward, PhD, co-founder of Tolemy Bio. “With that information, we can then predict the ideal supplement composition and concentrations to specifically enhance cell performance.”

Tackling the Billion-Dollar Bottleneck

The cell and gene therapy market is one of the fastest-growing sectors in biotechnology, with the global cell culture media market alone valued at over $7 billion in 2023 and projected to more than double within a decade. However, this growth has been hampered by significant manufacturing challenges. High costs, often running into hundreds of thousands of dollars per dose, and difficulties in scaling production have created a major bottleneck, limiting the widespread availability of these therapies.

By optimizing the very foundation of the manufacturing process, aiMOS™ aims to directly address these economic and logistical hurdles. The service is designed to improve viable cell yields, promote more favorable cell types (such as memory-like T cells), and stabilize performance from one manufacturing run to the next. The cumulative effect, according to the companies, is a lower cost per dose by reducing failed batches, minimizing rework, and optimizing the use of expensive reagents like cytokines.

This focus on efficiency and cost reduction is critical for an industry grappling with reimbursement challenges and the need to make therapies accessible to broader patient populations. Improving manufacturing consistency is not just an economic benefit; it is a core component of ensuring product quality and safety, a key concern for both developers and regulators.

A Strategic Alliance of Biology and Big Data

The collaboration is a synergistic pairing of a seasoned manufacturing expert with a nimble AI innovator. GeminiBio, founded in 1985 and a portfolio company of BelHealth Investment Partners, has a long-standing reputation in the biopharma industry. Its 57,000-square-foot cGMP facility in West Sacramento is a key asset, providing the infrastructure to produce the AI-designed media supplements under strict regulatory standards. The company’s human AB serum has been a staple in cell therapy workflows for over a decade, giving it deep insights into the market’s needs.

Tolemy Bio, based in Cambridge, UK, provides the advanced computational engine. As a TechBio company focused on creating an “AI-native control panel for the cell,” it represents the new wave of technology firms applying sophisticated algorithms to solve complex biological problems. The partnership allows Tolemy Bio to translate its powerful predictive models into tangible, cGMP-grade products through GeminiBio’s established manufacturing and quality systems.

“As cell therapies advance, customers need partners who provide both high-quality raw materials and pathways to process optimization,” noted Robert Perry, Chief Scientific Officer at GeminiBio. “aiMOS builds on our industry-leading position in human AB serum and expands our ability to help developers improve CQAs and reduce manufacturing risk.”

Navigating a New Regulatory Frontier

While the promise of AI in biomanufacturing is immense, it also introduces new regulatory complexities. Global regulators, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are still developing comprehensive frameworks for the use of AI/ML in cGMP environments. The primary focus is on ensuring that these complex algorithms are properly validated, that their decision-making processes are transparent and explainable, and that they consistently produce a safe and effective product.

For a service like aiMOS™ to gain widespread adoption, GeminiBio and Tolemy Bio will need to provide customers with robust documentation demonstrating the AI model's reliability and control. This includes proving data integrity, managing algorithm changes under strict change control protocols, and validating that the AI-optimized media consistently meets all predefined critical quality attributes.

GeminiBio's extensive experience with cGMP manufacturing and its ISO 13485 certification will be crucial in navigating this evolving landscape. By combining Tolemy Bio's AI with its own rigorous quality management system, the partnership is positioned to provide the validation and documentation required for clinical and commercial-stage therapeutic developers.

As the cell therapy industry strives to move from bespoke treatments for the few to scalable medicines for the many, the integration of advanced computational tools into the core of manufacturing represents a critical evolutionary step. The launch of aiMOS signals a tangible move in this direction, placing data-driven optimization at the forefront of the effort to make these life-saving therapies more consistent, affordable, and accessible.